LLY Eli Lilly and Co

   By Bowdeya Tweh 
 

ACQUIRER: Eli Lilly & Co., $89.49 billion market cap.

TARGET: AurKa Pharma Inc., a company working to develop a treatment being studied in early-stage clinical trials in multiple types of solid tumors.

PRICE: $110 million upfront, up to $465 million, based on regulatory and sales milestones.

STATUS: Under agreement.

RATIONALE: The acquisition helps Lilly expand its oncology drug pipeline.

HISTORY: Lilly sold the AK-01 compound in 2016 to TVM Capital Life Science, which then established AurKa as part of a venture fund.

STOCK: Shares in Lilly, up 2.8% over the past 12 months, were unchanged in premarket trading.

Write to Bowdeya Tweh at bowdeya.tweh@wsj.com

(END) Dow Jones Newswires

May 14, 2018 08:28 ET (12:28 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.